Trial Profile
AFX01-15: A Phase 2, Randomized, Active-controlled, Open-label, Multi-center Study of the Safety and Efficacy of Peginesatide for the Correction of Anemia in Patients With Chronic Renal Failure (CRF) Undergoing Hemodialysis and Not on Erythropoiesis Stimulating Agent (ESA) Treatment
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 May 2014
Price :
$35
*
At a glance
- Drugs Peginesatide (Primary) ; Epoetin alfa
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors Affymax
- 23 May 2014 New trial record